The Journal of International Medical Research 2012; 40:
|
|
- Bernice Fleming
- 5 years ago
- Views:
Transcription
1 The Journal of International Medical Research 2012; 40: Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment of Benign Prostatic Hyperplasia K-J JOO 1, W-S SUNG 2, S-H PARK 3, W-J YANG 4 AND T-H KIM 5 1 Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 2 Department of Urology, Seoul Red Cross Hospital, Seoul, Republic of Korea; 3 Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea; 4 Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea; 5 Department of Urology, Chung-Ang University College of Medicine, Seoul, Republic of Korea OBJECTIVE: This study compared a-blocker monotherapy with combination therapy involving an a-blocker and a 5-a reductase inhibitor for benign prostatic hyperplasia (BPH), according to baseline prostate volume. METHODS: Korean men diagnosed with BPH were randomized to 12 months treatment with 0.2 mg tamsulosin or 0.2 mg tamsulosin plus 0.5 mg dutasteride. Prostate specific antigen (PSA), prostate volume, transition zone volume (TZV), International Prostate Symptom Score (IPSS), maximal urinary flow rate (Q max ), postvoid residual urine volume and sexual function were assessed at baseline and after 12 months treatment. Variables were analysed based on baseline prostate volumes of 35 ml or > 35 ml. RESULTS: In total, 216 men with BPH were included. Combination therapy resulted in significant improvements in prostate volume, TZV, PSA, IPSS and Q max, which were most pronounced in men with a prostate volume > 35 ml. CONCLUSIONS: Tamsulosin mono - therapy was sufficient treatment for BPH in Korean men with a prostate volume 35 ml. Combination tamsulosin and dutasteride therapy provided greater benefits than tamsulosin monotherapy in men with BPH whose prostate volume was > 35 ml. KEY WORDS: PROSTATIC HYPERPLASIA; PROSTATE; TAMSULOSIN; DUTASTERIDE Introduction Benign prostatic hyperplasia (BPH) is a progressive disease that causes lower urinary tract symptoms (LUTS) which substantially affect quality of life for many patients. 1 Progression of BPH results in more severe LUTS, as well as other symptoms and episodes such as reduction of urinary flow rate, increased incidence of urinary infection, acute urinary retention 899
2 and increased incidence of surgery for BPH. 1,2 The α-adrenergic blockers (α-blockers) and 5α-reductase inhibitors (5-ARIs) are commonly used to treat patients with BPH. Prostatic smooth muscle plays a key role in the development of prostatic urethral pressure, which results in LUTS in patients with BPH. Since there are many α-adrenergic receptors within the prostatic smooth muscle, blocking the α-adrenergic receptor signal relieves the symptoms of BPH. The use of 5-ARIs reduces prostate volume by 20 30%, thereby relieving obstructive symptoms in BPH patients. 3,4 α-blocker monotherapy is commonly used to treat BPH patients who have a small prostate volume, whereas α-blocker/5-ari combination therapy is commonly used to treat BPH patients who have a large prostate volume. The Medical Therapy of Prostatic Symptoms (MTOPS) study indicated that combination therapy was beneficial when the prostate volume was > 40 ml and the serum prostate specific antigen (PSA) concentration was > 4.0 ng/ml. 5 It is unknown whether these standards also apply to the Korean population. The CombAT study suggested that combination therapy with 0.4 mg tamsolusin and 0.5 mg dutasteride was effective in patients with a prostate volume > 30 ml. 6 Unlike Western countries, where 0.4 mg tamsulosin once daily therapy is used, in Asian countries such as the Republic of Korea, China, Japan, Taiwan and Singapore, 0.2 mg tamsulosin once daily is the recommended dosage for treating BPH. The present study compared the efficacy and safety of monotherapy (0.2 mg tamsulosin, once daily) with combination therapy (0.2 mg tamsulosin/0.5 mg dutasteride, once daily), according to baseline prostate volume, in Korean men with BPH. Patients and methods STUDY POPULATION This randomized, controlled, open-label, multicentre study was performed between June 2008 and March 2010, and included consecutive patients diagnosed with BPH. The study was conducted at the following institutes in the Republic of Korea: Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul; Department of Urology, Seoul Red Cross Hospital, Seoul; Department of Urology, Haeundae Paik Hospital, Inje University College of Medicine, Busan; Department of Urology, Soonchunhyang University College of Medicine, Seoul; Department of Urology, Chung-Ang University College of Medicine, Seoul. Patient inclusion criteria were: age 40 years; diagnosis of BPH; International Prostate Symptom Score (IPSS) 13 points; 6 9 maximal urinary flow rate (Q max ) of 4 15 ml/s in a total voided volume 150 ml. Patients who had been treated previously for BPH were excluded from the study, as were patients diagnosed with prostate cancer, bladder cancer or other progressive diseases that could cause LUTS. Patients with > 200 ml of residual urine were also excluded. Approval for the study was granted by the Ethics Committee and Institutional Review Board at Chung-Ang University (reference No ). Written informed consent was obtained from all patients prior to the investigation. STUDY TREATMENT AND ASSESSMENTS Selected patients were randomized into one of the two treatment groups according to a computer-generated randomization schedule at study entry, and treated either with α- blocker monotherapy (0.2 mg tamsulosin, orally, once daily; Group 1) or with α- 900
3 blocker/5-ari combination therapy (0.2 mg tamsulosin, orally, once daily plus 0.5 mg dutasteride, orally, once daily; Group 2) for 12 months. Patients were asked to attend follow-up appointments at their treatment centres every 3 months. Prostate volume, transition zone volume (TZV), uroflowmetry and residual urine volume were measured before and after 12 months treatment. In addition, participants were asked to complete the following questionnaires: the IPSS, with symptoms classified as mild (scores 0 7), moderate (scores 8 19), or severe (scores 20 35); 9 the International Index of Erectile Function (IIEF), which classifies the severity of erectile dysfunction into five categories (severe [scores 5 7], moderate [scores 8 11], mild to moderate [scores 12 16], mild [scores 17 21], and no erectile dysfunction [scores 22 25]); 10 and the Male Sexual Health Questionnaire (MSHQ: 11 out of the 25 items, only the seven items for ejaculation were assessed in the present study). Each questionnaire was completed before and after 12 months treatment and scores were compared to determine whether there were any significant changes over time. Treatment effects of mono- and combination therapy on prostate volume were compared in patients, divided into those with a baseline prostate volume 35 ml and those with a baseline volume > 35 ml. The primary endpoint was the change in IPSS or Q max from baseline for monotherapy versus combination therapy in patients with a baseline prostate volume 35 ml or > 35 ml. Adverse events were assessed by the investigator at every 3-month follow-up visit. STATISTICAL ANALYSES Statistical analyses were carried out using SPSS statistical software, version 15.0 (SPSS Inc., Chicago, IL, USA) for Windows. Differences between the two treatment groups were compared using Student s t-test and the incidence of adverse events was analysed using Pearson s χ 2 -test. A P-value < 0.05 was considered to be statistically significant. Results In total, 216 participants met the inclusion criteria and were enrolled. Of these, 23 (10.6%) were unable to complete the study: eight (3.7%) dropped out due to a desire to stop treatment; five (2.3%) were excluded due to modification of the treatment plan to surgical intervention; five (2.3%) dropped out due to adverse events such as impotence and retrograde ejaculation; four (1.9%) dropped out due to orthostatic hypotension; one (0.5%) dropped out due to dyspepsia. A total of 95 patients in Group 1 and 98 patients in Group 2 completed the trial. Baseline parameters are shown in Table 1. There were no significant between-group differences in terms of baseline parameters. After 12 months treatment, patients in Group 1 showed a significant reduction in IPSS and residual urine volume, and a significant increase in Q max (Table 1; P < 0.05, all comparisons). In Group 2, a significant reduction in PSA concentration, prostate volume, TZV, IPSS and residual urine volume, and a significant increase in Q max, were observed (Table 1; P < 0.05, all comparisons). IIEF and MSHQ scores did not change significantly in either group across the study period (Table 1). In total, 52 patients from Group 1 and 51 patients from Group 2 had a baseline prostate volume 35 ml, whereas 43 patients from Group 1 and 47 patients from Group 2 had a baseline prostate volume > 35 ml. At baseline there were no significant differences between Groups 1 and 2, stratified by prostate volume (Tables 2 and 3). 901
4 TABLE 1: Baseline parameters and changes after 12 months treatment with a-blocker monotherapy (Group 1) compared with combination therapy with an a-blocker plus a 5a-reductase inhibitor (Group 2) for the treatment of benign prostatic hyperplasia in Korean patients Group 1 Group 2 n = 95 n = 98 Parameter Baseline 12 months Difference Baseline 12 months Difference Age, years ± ± 7.77 PV, ml ± ± ± ± ± ± 6.14* TZV, ml ± ± ± ± ± ± 2.32* PSA, ng/ml 1.70 ± ± ± ± ± ± 0.68* IPSS ± ± ± 3.93* ± ± ± 2.91* Q max, ml/s ± ± ± 3.45* ± ± ± 2.07* PVR, ml ± ± ± 17.51* ± ± ± 15.52* IIEF score ± ± ± ± ± ± 5.28 MSHQ score ± ± ± ± ± ± 3.75 Data presented as mean ± SD. *P < 0.05, baseline versus after 12 months treatment; Student s t-test. Group 1, monotherapy with 0.2 mg tamsulosin, orally once daily; Group 2, combination therapy with 0.2 mg tamsulosin, orally once daily plus 0.5 mg dutasteride, orally once daily. PV, prostate volume; TZV, transition zone volume; PSA, prostate specific antigen; IPSS, International Prostate Symptom Score; 6 9 Q max, maximal urinary flow rate; PVR, postvoid residual urine volume; IIEF, International Index of Erectile Function; 10 MSHQ, Male Sexual Health Questionnaire
5 TABLE 2: Baseline parameters and changes after 12 months treatment in Korean patients with benign prostatic hyperplasia with a baseline prostate volume 35 ml who were treated with either a-blocker monotherapy (Group 1) or combination therapy with an a-blocker plus a 5a-reductase inhibitor (Group 2) Group 1 Group 2 n = 52 n = 51 Parameter Baseline 12 months Difference Baseline 12 months Difference Age, years ± ± 7.42 PV, ml ± ± ± ± ± ± 0.41* TZV, ml ± ± ± ± ± ± 0.10* PSA, ng/ml 1.23 ± ± ± ± ± ± 0.05* IPSS ± ± ± ± ± ± 0.40 Q max, ml/s ± ± ± ± ± ± 0.22 PVR, ml ± ± ± ± ± ± 2.19 IIEF score ± ± ± ± ± ± 0.81 MSHQ score ± ± ± ± ± ± 0.44 Data presented as mean ± SD. *P < 0.05, difference in Group 1 versus difference in Group 2; Student s t-test. Group 1, monotherapy with 0.2 mg tamsulosin, orally once daily; Group 2, combination therapy with 0.2 mg tamsulosin, orally once daily plus 0.5 mg dutasteride, orally once daily. PV, prostate volume; TZV, transition zone volume; PSA, prostate specific antigen; IPSS, International Prostate Symptom Score; 6 9 Q max, maximal urinary flow rate; PVR, postvoid residual urine volume; IIEF, International Index of Erectile Function; 10 MSHQ, Male Sexual Health Questionnaire
6 TABLE 3: Baseline parameters and changes after 12-months treatment in Korean patients with benign prostatic hyperplasia with a baseline prostate volume > 35 ml who were treated with either a-blocker monotherapy (Group 1) or combination therapy with an a-blocker plus a 5a-reductase inhibitor (Group 2) Group 1 Group 2 n = 43 n = 47 Parameter Baseline 12 months Difference Baseline 12 months Difference Age, years ± ± 7.66 PV, ml ± ± ± ± ± ± 0.76* TZV, ml ± ± ± ± ± ± 0.40* PSA, ng/ml 2.25 ± ± ± ± ± ± 0.12* IPSS ± ± ± ± ± ± 0.43 Q max, ml/s ± ± ± ± ± ± 0.32* PVR, ml ± ± ± ± ± ± 2.26 IIEF score ± ± ± ± ± ± 0.65 MSHQ score ± ± ± ± ± ± 0.63 Data presented as mean ± SD. *P < 0.05, difference in Group 1 versus difference in Group 2; Student s t-test. Group 1, monotherapy with 0.2 mg tamsulosin, orally once daily; Group 2, combination therapy with 0.2 mg tamsulosin, orally once daily plus 0.5 mg dutasteride, orally once daily. PV, prostate volume; TZV, transition zone volume; PSA, prostate specific antigen; IPSS, International Prostate Symptom score; 6 9 Q max, maximal urinary flow rate; PVR, postvoid residual urine volume; IIEF, International Index of Erectile Function; 10 MSHQ, Male Sexual Health Questionnaire
7 After 12 months treatment in patients with a baseline prostate volume 35 ml, prostate volume increased by 2.4% in Group 1 but decreased by 20.6% in Group 2, TZV increased by 2.0% in Group 1 but decreased by 17.0% in Group 2, and PSA concentration decreased by 2.4% in Group 1 and by 38.5% in Group 2 (Table 2). There was a significant between-group difference in the change from baseline at 12 months for all three parameters (Table 2; P < 0.05). After 12 months treatment in patients with a baseline prostate volume > 35 ml, prostate volume increased by 1.6% in Group 1 but decreased by 31.0% in Group 2, TZV increased by 1.4% in Group 1 but decreased by 21.3% in Group 2, PSA concentration decreased by 4.0% and by 42.6% in Groups 1 and 2, respectively, and Q max increased by 22.4% and by 41.5% in Groups 1 and 2, respectively (Table 3). There was a significant between-group difference in the change from baseline at 12 months for all four parameters (Table 3; P < 0.05). There were no significant between-group differences for the remaining variables after 12 months in men with a baseline prostate volume of 35 ml or > 35 ml (Tables 2 and 3). The incidence of adverse events recorded during the study is reported in Table 4; there were no significant between-group differences. Discussion The clinical effects of α-blockers in relieving obstructive symptoms in patients with BPH, by relaxing prostatic smooth muscles, are well defined. 7,12 Tamsulosin, a selective α 1a - adrenergic receptor blocker, is a commonly used treatment for BPH and has proven efficacy and a good safety profile. 8,13 15 The 5-ARIs block the action of the 5α-reductase enzymes that convert testosterone into dihydrotestosterone (DHT, which normally promotes prostate growth) and reduce prostate size to relieve obstructive symptoms. 3 Dutasteride inhibits both isoforms of 5α-reductase (types I and II), and has a 45-fold greater affinity for type I and a 2.5-fold greater affinity for type II than finasteride. As a result of this higher affinity, dutasteride effectively inhibits DHT much more rapidly than finasteride. 16 The management of BPH focuses not only on reduction of LUTS, but also on prevention of BPH progression. Several studies have demonstrated that the use of 5-ARIs reduces adverse events in the progression of BPH. 3,5,7 The PREDICT study and the Veterans Affairs Cooperative Study reported that 12 months TABLE 4: Adverse events recorded during 12 months treatment with a-blocker monotherapy (Group 1) compared with combination therapy with an a-blocker plus a 5a-reductase inhibitor (Group 2) for the treatment of Korean men with benign prostatic hyperplasia Group 1 Group 2 Event n = 95 n = 98 Erectile dysfunction 3 (3.2) 8 (8.2) Decreased libido 4 (4.2) 9 (9.2) Retrograde ejaculation 8 (8.4) 9 (9.2) Dizziness 2 (2.1) 3 (3.1) Data presented as n (%) of patients. There were no statistically significant difference between groups (P 0.05 for all comparisons); Pearson s χ 2 -test. Group 1, monotherapy with 0.2 mg tamsulosin, orally once daily; Group 2, combination therapy with 0.2 mg tamsulosin, orally once daily plus 0.5 mg dutasteride, orally once daily. 905
8 combination therapy with an α-blocker plus a 5-ARI was no more beneficial than α- blocker monotherapy in terms of symptom relief and urine flow rate. 7,17 The 4-year PLESS study, however, 18 reported that finasteride therapy reduced the need for surgical treatment by 50%. Moreover, according to the MTOPS study (which lasted for 4.5 years), the risk of acute urinary retention was lower in groups treated with finasteride or with the combination of an α- blocker and 5-ARI, compared with groups treated with doxazosin. 5 The MTOPS study also reported that α-blocker monotherapy only delayed BPH-associated adverse events (such as acute urinary retention), whereas combination therapy with an α-blocker and a 5-ARI reduced both the risk of adverse events and the need for surgical intervention. 5 Combination therapy with an α-blocker and a 5-ARI is theoretically ideal because α- blockers treat biokinetic factors associated with prostatic smooth muscle and 5-ARIs treat anatomical factors associated with BPH. The optimal combination has, however, yet to be determined. In patients from the Republic of Korea, it has been reported that there are no significant differences between combination therapy and monotherapy in terms of treatment effects for a prostate volume < 40 ml. 19 The MTOPS study reported that combination therapy was effective in patients with a prostate volume 40 ml. 5 Even though the frequency of LUTS in the Korean population is the same as that in Western populations, prostate volume and PSA concentrations are lower in the Korean population. Multicentre research in Korean patients indicates that the 40-ml standard for a large prostate in Western populations can be translated to 35 ml in the local Korean population. 20 Thus, the present study used 35 ml as the standard prostate volume to differentiate large and small prostates when comparing the treatment effects of monotherapy and combination therapy. In patients with a baseline prostate volume 35 ml, prostate volume, TZV and PSA concentrations were significantly reduced after 12 months combination therapy compared with monotherapy. Symptoms were relieved in both groups and changes in the IPSS, Q max, residual urine volume and other variables were not significantly different. In patients with a baseline prostate volume > 35 ml, decreases in prostate volume, TZV and PSA concentrations after combination therapy were greater than those observed in the group with a baseline prostate volume 35 ml. Thus, the reductions in PSA and prostate volume were greater in patients with an initially larger prostate volume. In addition, Q max was significantly increased in the combination therapy group compared with the monotherapy group with a baseline prostate volume > 35 ml. Most of the adverse events reported in the present study were related to sexual function and were more frequently observed in the combination therapy group, although such symptoms were minimal and were not significantly different between the two groups. The frequency of retrograde ejaculation (which is a known side-effect of α 1a -selective blockers) was the same in both groups. Adverse events observed with 5-ARIs (such as erectile dysfunction and decreased libido) were more frequently reported in patients receiving combination therapy, although the difference was not significantly different between the two groups. In addition, there were no significant betweengroup differences in the IIEF and MSHQ scores. It could be inferred that psychological factors play a role in the development of 906
9 side-effects, but that these events are not substantial enough to affect daily life. In conclusion, in the population of Korean men that was studied, α-blocker monotherapy was a suitable treatment for BPH patients with a prostate volume 35 ml. In Korean BPH patients with a prostate volume > 35 ml, α-blocker plus 5-ARI combination therapy was more beneficial than α-blocker monotherapy. Conflicts of interest The authors had no conflicts of interest to declare in relation to this article. Received for publication 23 January 2012 Accepted subject to revision 5 February 2012 Revised accepted 13 April 2012 Copyright 2012 Field House Publishing LLP References 1 Welch G, Weinger K, Barry MJ: Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002; 59: Roehrborn CG, Bruskewitz R, Nickel GC, et al: Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol 2000; 37: McConnell JD, Wilson JD, George FW, et al: Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: Roehrborn CG, McConnell J, Bonilla J, et al: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR longterm efficacy and safety study. J Urol 2000; 163: McConnell JD, Roehrborn CG, Bautista OM, et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: Roehrborn CG, Siami P, Barkin J, et al: The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: Kirby RS, Roehrborn C, Boyle P, et al: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: Lapitan MC, Acepcion V, Mangubat J: A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. J Int Med Res 2005; 33: Abrams P, Chapple C, Khoury S, et al: Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009; 181: Rosen RC, Riley A, Wagner G, et al: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: Rosen RC, Catania J, Pollack L, et al: Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: Lepor H, Williford WO, Barry MJ, et al: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: Wilt TJ, MacDonald R, Nelson D: Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol 2002; 167: Lyseng-Williamson KA, Jarvis B, Wagstaff AJ: Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62: Watanabe T, Ozono S, Kageyama S: A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res 2011; 39: Bartsch G, Rittmaster RS, Klocker H: Dihydrotestosterone and the concept of 5alphareductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37: Flanigan RC, Reda DJ, Wasson JH, et al: 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs Cooperative Study. J Urol 1998; 160:
10 18 McConnell JD, Bruskewitz R, Walsh P, et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: Jung SI, Kim SO, Min KD, et al: Efficacy of α- blocker and finasteride combination therapy for benign a prostatic hyperplasia with a prostate volume less than 40 grams. Korean J Urol 2003; 44: [in Korean, English abstract]. 20 Cho JS, Kim CI, Seong DH, et al: Cut-off point of large prostate volume for the patients with benign prostatic hyperplasia. Korean J Urol 2005; 46: [in Korean, English abstract]. Author s address for correspondence Professor Tae Hyoung Kim Department of Urology, Chung-Ang University College of Medicine, Heuksuk-dong, Dongjak-gu, Seoul , Republic of Korea. kthlmk@nate.com 908
α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationBenign Prostatic Hypertrophy (BPH) is the most
Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationAlpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride
European Urology European Urology 44 (2003) 461 466 Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride J.
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationRecommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationThe Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia
J Prev Med Public Health 2009;42(3):165-170 DOI: 103961/jpmph2009423165 The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia Joongyub Lee 1) Nam-Kyoung Choi 13) Sun-Young
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationHow Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
available at www.sciencedirect.com journal homepage: www.europeanurology.com How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGuideline for the primary care management of male lower urinary tract symptoms
review Article GUIDELINES FOR LUTS M.J. SPEAKMAN et al. As my Comment in the first section of the journal suggested, the MTOPS results have offered the possibility to general practitioners of reducing
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationComments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
ORIGINAL PAPER DOI: 10.4081/aiua.2015.4.312 Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs Furio Pirozzi Farina, Antonella Pischedda Andrological Urology Unit,
More informationMedical Therapy for Benign Prostatic Hyperplasia Present and Future Impact
REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationEvaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia
469245JMHXXX10.1177/1557988312469245A merican Journal of Men s HealthKruep et al. Article Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia American Journal
More informationImpact of 5-Alpha Reductase Inhibitors Treatment for Benign Prostatic Hyperplasia on Erectile Dysfunction: A Meta-Analysis
International Journal of Clinical Urology 2017; 1(1): 1-6 http://www.sciencepublishinggroup.com/j/ijcu doi: 10.11648/j. ijcu.20170101.11 Review Article Impact of 5-Alpha Reductase Inhibitors Treatment
More informationLast Review Status/Date: December Summary
Section: Surgery Effective Date: January 15, 2016 Subject: Prostatic Urethral Lift Page: 1 of 9 Last Review Status/Date: December 2015 Summary Benign prostatic hyperplasia (BPH) is a common condition in
More informationEffects of prostatic inflammation on LUTS and alpha blocker treatment outcomes
ORIGINAL ARTICLE Vol. 40 (3): 356-366, May - June, 2014 doi: 10.1590/S1677-5538.IBJU.2014.03.09 Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes Ha Na Lee 1, Tae-Hyoung Kim
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationIntroduction. Original Article: Clinical Investigation
International Journal of Urology (2015) 22, 582--587 doi: 10.1111/iju.12741 Original Article: Clinical Investigation Treatment satisfaction and clinically meaningful symptom improvement in men with lower
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationSystematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms
EUROPEAN UROLOGY 64 (2013) 228 243 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Benign Prostatic Hyperplasia Editorial by Herbert
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationImpact of Changing Trends in Medical Therapy on Surgery for Benign Prostatic Hyperplasia Over Two Decades
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.1.23 Voiding Dysfunction Impact of Changing Trends in Medical Therapy on Surgery for Benign Prostatic Hyperplasia Over Two Decades Se Young Choi,
More informationVoiding Dysfunction. Hyo Serk Lee, Sae Woong Kim 1, Seung-June Oh 2, Myung-Soo Choo 3, Kyu-Sung Lee
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.3.178 Voiding Dysfunction Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More informationEffects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.10.697 Sexual Dysfunction/Male Infertility Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive
More informationREVIEW The role of combination medical therapy in benign prostatic hyperplasia
(2008) 20, S33 S43 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The role of combination medical therapy in benign prostatic hyperplasia Department of
More informationEffects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2014 August 32(2): 99-104 http://dx.doi.org/10.5534/wjmh.2014.32.2.99 Original Article Effects of Tamsulosin on Premature Ejaculation in Men with
More informationWhat can the primary care physician do? Brian W. Ellis
What can the primary care physician do? Brian W. Ellis Consultant Urological Surgeon at Ashford & St Peter s 1983-2007 Currently Consultant Urological Surgeon at Cobham Hospital Visiting Professor at Middlesex
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationBenign Prostatic Hyperplasia: Update on Innovative Current Treatments
Benign Prostatic Hyperplasia: Update on Innovative Current Treatments Michael Ferrandino, MD As.soc Professor Director of Minimally Invasive Urologic Surgery Division of Urologic Surgery Duke University
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: None Prostatic Urethral Lift Description Benign prostatic hyperplasia (BPH) is a common condition in older individuals that can
More informationOriginal Article Japanese Urological Association. International Journal of Urology (2006) 13,
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd2006130014051409Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationKorean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey
Original Article DOI 10.3349/ymj.2010.51.2.248 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 51(2):248-252, 2010 Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic
More informationProstatic Urethral Lift
Protocol Prostatic Urethral Lift (701151) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization No Review Dates: 05/17, 01/18 Preauthorization is not required. The following
More informationMonth/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationGuidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)
Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) M. Oelke (chairman), A. Bachmann, A. Descazeaud, M. Emberton, S. Gravas, M.C. Michel,
More informationGENDER HEALTH. Benign Prostatic Hyperplasia. Medical and Surgical Treatment Options
GENDER HEALTH Benign Prostatic Hyperplasia Medical and Surgical Treatment Options ABSTRACT Benign prostatic hyperplasia (BPH) affects the aging male. Treatment options vary widely. Some men will elect
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki , Japan
BioMed Research International Volume 216, Article ID 4975851, 5 pages http://dx.doi.org/1.1155/216/4975851 Clinical Study Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary
More informationOriginal Article - Sexual Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.9.608 Original Article - Sexual Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.9.608&domain=pdf&date_stamp=2014-09-16
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationPROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA
St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More informationOriginal Article - Voiding Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.335 Original Article - Voiding Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.335&domain=pdf&date_stamp=2014-05-16
More informationMedical Coverage Policy Prostatic Urethral Lifts
Medical Coverage Policy Prostatic Urethral Lifts EFFECTIVE DATE:12 01 2018 POLICY LAST UPDATED: 10 03 2017 OVERVIEW Benign prostatic hyperplasia is a common condition in older men that can lead to increased
More informationBenign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful to Primary Care
Volume 1, Number 1 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and Prostate Health,
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationj 727
Efficacy and Safety of the Coadministration of Tadalafil Once Daily with Finasteride for 6 Months in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: January 15, 2019 Related Policies: None Prostatic Urethral Lift Description Benign prostatic hyperplasia (BPH) is a common condition in older individuals that
More informationEuropean Healthcare Innovation Leadership Network
MAY 2008 The Value Proposition of Medicines to Treat Benign Prostatic Hyperplasia: Introduction The following case study examines the evolution of Avodart, a drug manufactured by GSK that is currently
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationDepartment of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
NEW PERSPECTIVES ON BPH 5- -Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia Claus G. Roehrborn, MD Department of Urology, The University of Texas Southwestern Medical Center
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationRole of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
European Review for Medical and Pharmacological Sciences 2017; 21: 4941-4945 Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label,
More informationREPORTS. Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate
Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate Michael James Naslund, MD, MBA; Muta M. Issa, MD, MBA; Amy L. Grogg, PharmD; Michael T. Eaddy, PharmD, PhD; and Libby Black, PharmD
More informationHee Young Park, Joo Yong Lee, Sung Yul Park, Seung Wook Lee, Yong Tae Kim, Hong Yong Choi, Hong Sang Moon
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.2.92 Voiding Dysfunction Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal
More informationPATIENT INFORMATION 2017 NeoTract, Inc. All rights reserved. Printed in the USA. MAC Rev A
PATIENT INFORMATION OVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1 BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationLasers in Urology. Sae Woong Choi, Yong Sun Choi, Woong Jin Bae, Su Jin Kim, Hyuk Jin Cho, Sung Hoo Hong, Ji Youl Lee, Tae Kon Hwang, Sae Woong Kim
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.12.824 Lasers in Urology 120 W Greenlight HPS Laser Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia in
More informationA Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia
ORIGINAL RESEARCH www.ijcmr.com A Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia Rupam Deori 1, Bijoyananda Das 2, Mustafa Abdur Rahman 3 ABSTRACT
More informationCan men with prostates sized 80 ml or larger be managed conservatively?
Original Article - Lower Urinary Tract Dysfunction Investig Clin Urol 2017;58:359-364. pissn 2466-0493 eissn 2466-054X Can men with prostates sized 80 ml or larger be managed conservatively? Alvin Lee,
More informationMedical management of Benign Prostate Hyperplasia: New insights
INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN BIOLOGY AND MEDICINE ISSN: 2455-944X www.darshanpublishers.com DOI:10.22192/ijcrbm Volume 2, Issue 5-2017 Original Research Article Medical management of Benign
More information10/9/2015. Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University
Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University 1. Explain the pathophysiology of benign prostatic hyperplasia (BPH),
More informationOptimising the Medical Management of Benign Prostatic Hyperplasia
European Urology European Urology 45 (2004) 411 419 Review Optimising the Medical Management of Benign Prostatic Hyperplasia Michael Marberger a,*, Richard Harkaway b, Jean de la Rosette c a Department
More informationClass Update: Benign Prostatic Hyperplasia (BPH)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationMedical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
REVIEW Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily Claus G Roehrborn 1 Raymond C Rosen 2 1 Department of Urology, University of Texas Southwestern
More informationPrevalence of Benign Prostatic Hyperplasia on Jeju Island: Analysis from a Cross-sectional Community-based Survey
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2012 August 30(2): 131-137 http://dx.doi.org/10.5534/wjmh.2012.30.2.131 Original Article Prevalence of Benign Prostatic Hyperplasia on Jeju Island:
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationA Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
Chattagram Maa-O-Shishu Hospital Medical College Journal Original Article A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
More informationTherapeutic Class Overview Benign Prostatic Hyperplasia (BPH) Treatments
Therapeutic Class Overview Benign Prostatic Hyperplasia (BPH) Treatments Therapeutic Class Overview/Summary: The agents approved for the treatment of signs and symptoms of benign prostatic hyperplasia
More informationThe Hallmarks of BPH Progression and Risk Factors
European Urology Supplements European Urology Supplements 2 (23) 2 7 The Hallmarks of BPH Progression and Risk Factors M. Emberton * Institute of Urology and Nephrology, University College London, 48 Riding
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationINTRODUCTION MISCELLANEOUS
MISCELLANEOUS Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial Hossein Karami*, Amin Hassanzadeh-Hadad,
More information